Posaconazole泊沙康唑,171228-49-2

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Posaconazole

CAS No. : 171228-49-2

MCE 国际站：Posaconazole

产品活性：Posaconazole 是一种广谱的，二代三唑类物质，具有抗真菌作用。

研究领域：Anti-infection

作用靶点：Fungal  |  Parasite

In Vitro: Posaconazole has potent trypanocidal activity. Amiodarone acts synergistically with Posaconazole. Posaconazole also affects and disrupts Ca²⁺ homeostasis in T. cruzi. Posaconazole blocks the biosynthesis of ergosterol, which is essential for parasite survival. Posaconazole has a clear, dose-dependent effect on proliferation of the epimastigote (extracellular) stages, with a minimal inhibitory concentration of 20 nM and an IC₅₀ of 14 nM. Against the clinically relevant intracellular amastigote form of the parasite, Posaconazole is even more potent. Posaconazole has the minimal inhibitory concentration and IC₅₀ values of 3 nM and 0.25 nM. Posaconazole is active against isolates of Candida and Aspergillus spp. that exhibit resistance to Fluconazole, Voriconazole, and Amphotericin B and is much more active than the other triazoles against zygomycetes.

In Vivo: Treatment of infected animals with amiodarone alone reduces parasitemia, increases survival 60 days pi (0% for untreated controls vs 40% for amiodarone-treated animals) and, when given in combination with Posaconazole, delays the development of parasitemia.
Coadministration of Posaconazole and Boost Plus increases drug exposure compared to the administration of Posaconazole alone in the fasted state. Food, particularly meals high in fat content, significantly increases Posaconazole bioavailability. Systemic exposure to Posaconazole increases 4- and 2.6-fold when it is consumed with a high-fat and nonfat meal, respectively.
Posaconazole and Amiodarone may constitute an effective anti-T. cruzi therapy with low side effect.
At twice-daily doses of ≥ 15 mg/kg of body weight, Posaconazole prolongs the survival of the mice and reduces tissue burden.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Antifungal Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Antiparasitic Compound library  |  Rare Diseases Drug Library  |  Children’s Drug Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Ferrostatin-1  |  Rapamycin  |  Cycloheximide  |  Chloroquine  |  Puromycin dihydrochloride  |  Staurosporine  |  Resveratrol  |  Hygromycin B  |  Tunicamycin  |  Doxycycline hyclate  |  Oligomycin  |  Acetaminophen  |  Anisomycin  |  Camptothecin  |  Metronidazole  |  Kaempferol  |  Filipin complex  |  Amphotericin B  |  Dihydroartemisinin  |  Calcimycin  |  Hydroxychloroquine sulfate  |  Niclosamide  |  Artesunate  |  Berberine chloride  |  Monensin sodium salt  |  Nystatin

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds